Literature DB >> 11870155

Recurrent ovarian cancer: evidence-based treatment.

Robert F Ozols.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 11870155     DOI： 10.1200/JCO.2002.20.5.1161

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  30 in total

1.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Authors:  Teresa Granato; Cecilia Midulla; Flavia Longo; Barbara Colaprisca; Luigi Frati; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-04-13

Review 2.  Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

Authors:  Terence C Chua; Greg Robertson; Winston Liauw; Rhonda Farrell; Tristan D Yan; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-23       Impact factor: 4.553

3.  Circ-EEF2 facilitated autophagy via interaction with mir-6881-3p and ANXA2 in EOC.

Authors:  Min Yong; Jianguo Hu; Hongtao Zhu; Xinwei Jiang; Xiaolin Gan; Lina Hu
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 6.166

4.  The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Authors:  Fang Fang; Joanne Munck; Jessica Tang; Pietro Taverna; Yinu Wang; David F B Miller; Jay Pilrose; Gavin Choy; Mohammad Azab; Katherine S Pawelczak; Pamela VanderVere-Carozza; Michael Wagner; John Lyons; Daniela Matei; John J Turchi; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

5.  HE4: a new potential early biomarker for the recurrence of ovarian cancer.

Authors:  Emanuela Anastasi; Giulia Giovanna Marchei; Valentina Viggiani; Giuseppina Gennarini; Luigi Frati; Maria Gabriella Reale
Journal:  Tumour Biol       Date:  2010-01-23

6.  HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.

Authors:  Cecilia Midulla; Lucia Manganaro; Flavia Longo; Valentina Viggiani; Luigi Frati; Teresa Granato; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-03-20

7.  Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.

Authors:  Takiko Daikoku; Dingzhi Wang; Susanne Tranguch; Jason D Morrow; Sandra Orsulic; Raymond N DuBois; Sudhansu K Dey
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

8.  Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.

Authors:  Kimio Ushijima; Toshiharu Kamura; Kazuo Tamura; Kazuo Kuzuya; Toru Sugiyama; Kiichiro Noda; Kazunori Ochiai
Journal:  Int J Clin Oncol       Date:  2011-11-30       Impact factor: 3.402

Review 9.  Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.

Authors:  P A Vasey
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

10.  Treatment for recurrent ovarian cancer-at first relapse.

Authors:  Kimio Ushijima
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.